ALERTS: UNILATERAL PRACTICES - EUROPEAN UNION - PHARMACEUTICAL SECTOR - COMMITMENTS - EXCESSIVE PRICES

Commitments: The European Commission accepts and makes binding the commitments of one pharmaceutical company to reduce the prices of six anti-cancer drugs by 73% for ten years, and sends a strong signal to other pharmaceutical companies about excessive pricing practices (Aspen)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. On 10 February 2021, the Commission accepted and made binding the commitments commitments submitted in their final versions on January 28, 2021 by Aspen Pharmaceuticals to address competition concerns about excessive pricing implemented since 2012 on six key cancer drugs in that patients' lives sometimes depend on their administration.

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • L’actu-concurrence (Paris)

Quotation

Alain Ronzano, Commitments: The European Commission accepts and makes binding the commitments of one pharmaceutical company to reduce the prices of six anti-cancer drugs by 73% for ten years, and sends a strong signal to other pharmaceutical companies about excessive pricing practices (Aspen), 10 February 2021, Concurrences N° 2-2021, Art. N° 99313, www.concurrences.com

Visites 214

All reviews